Two novel investigational drugs targeting antibiotic-resistant infections move into advanced development with HHS

  01 October 2020

Two innovative, cutting-edge and potential first-in-class investigational drugs to treat antibiotic-resistant infections will move into advanced stages of development with support from the U.S. Department of Health and Human Services (HHS).

Under the partnership agreements announced today, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, will provide advanced development expertise and funding to each company to support Phase 2 and Phase 3 clinical trials and other activities required to seek approval from the U.S. Food and Drug Administration (FDA).

BARDA will provide an initial $7.36 million and up to a total of $76.9 million over nine-and-a-half years to Vedanta Biosciences, Inc., of Cambridge, Massachusetts, to support development of VE303 to prevent C. difficile infections. BARDA also will provide an initial $11 million and up to a total of $77 million over five years to Locus Biosciences of Morrisville, North Carolina, part of a $144 million program to develop LBP-EC01 to treat recurrent UTIs including those caused by antibiotic-resistant E. coli.

 

Further reading: Public Health Emergency
Author(s): Public Health Emergency
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!